Over the last 60 years, there were many attempts to develop novel therapies for schizophrenia that exert antipsychotic action without blocking dopamine D2 receptors; however, essentially, all these approaches failed in the clinical trials. The gene discussed is DRD2; the disease is schizophrenia.